MARKET

MNLO

Menlo
MNLO
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-2.0651
27.26
14.98
1,071,543,029.85
Do Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?
Zacks.com · 12/13/2021 17:08
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Lags Revenue Estimates
Zacks.com · 11/10/2021 13:45
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks.com · 10/28/2021 04:43
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
Zacks.com · 08/12/2021 14:15
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks.com · 08/05/2021 19:01
Were Hedge Funds Right About Piling Into Menlo Therapeutics Inc. (MNLO)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 08/07/2020 13:03
Menlo Therapeutics EPS misses by $0.93, beats on revenue
Menlo Therapeutics (NASDAQ:MNLO): Q2 GAAP EPS of -$1.21 misses by $0.93. Revenue of $11.7M beats by $9.66M. Shares -1.9% PM. Press Release
seekingalpha · 08/06/2020 16:13
Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates
Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06/2020 15:25
More
No Data
Learn about the latest financial forecast of MNLO. Analyze the recent business situations of Menlo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MNLO stock price target is 5.50 with a high estimate of 10.00 and a low estimate of 3.000.
High10.00
Average5.50
Low3.000
Current 6.39
EPS
Actual
Estimate
-0.26-0.17-0.070.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 106
Institutional Holdings: 14.69M
% Owned: 25.35%
Shares Outstanding: 167.69M
TypeInstitutionsShares
Increased
8
215.38K
New
7
309.20K
Decreased
14
1.51M
Sold Out
17
2.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+2.68%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
President/Chief Executive Officer/Director
David Domzalski
Chief Financial Officer/Treasurer
Tyler Zeronda
Chief Scientific Officer
Iain Stuart
General Counsel/Secretary
Mutya Harsch
Lead Director/Independent Director
Patrick Lepore
Director
Steven Basta
Independent Director
Sharon Barbari
Independent Director
Anthony Bruno
Independent Director
Elisabeth Sandoval
No Data
No Data

Webull offers kinds of Menlo stock information, including NASDAQ:MNLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNLO stock methods without spending real money on the virtual paper trading platform.